1 |
Chen J, Liu Q, Liu GH, Zheng WB, Hong SJ, Sugiyama H, Zhu XQ, Elsheikha HM. Toxocariasis: a silent threat with a progressive public health impact. Infect Dis Poverty 2018; 7: 59. https://doi.org/10.1186/s40249-018-0437-0
DOI
|
2 |
Taylor MR. The epidemiology of ocular toxocariasis. J Helminthol 2001; 75: 109-118.
|
3 |
Woodhall D, Starr MC, Montgomery SP, Jones JL, Lum F, Read RW, Moorthy RS. Ocular toxocariasis: epidemiologic, anatomic, and therapeutic variations based on a survey of ophthalmic subspecialists. Ophthalmology 2012; 119: 1211-1217. https://doi.org/10.1016/j.ophtha.2011.12.013
DOI
|
4 |
Scaramuzzi M, Querques G, Spina CL, Lattanzio R, Bandello F. Repeated intravitreal dexamethasone implant (Ozurdex) for diabetic macular edema. Retina 2015; 35: 1216-1222. https://doi.org/10.1097/iae.0000000000000443
DOI
|
5 |
Fassbender Adeniran JM, Jusufbegovic D, Schaal S. Common and rare ocular side-effects of the dexamethasone implant. Ocul Immunol Inflamm 2017; 25: 834-840. https://doi.org/10.1080/09273948.2016.1184284
DOI
|
6 |
Auer H, Walochnik J. Toxocariasis and the clinical spectrum. Adv Parasitol 2020; 109: 111-130. http://doi.org/10.1016/bs.apar.2020.01.005
DOI
|
7 |
Pak KY, Park SW, Byon IS, Lee JE. Ocular toxocariasis presenting as bilateral scleritis with suspect retinal granuloma in the nerve fiber layer: a case report. BMC Infect Dis 2016; 16: 426. https://doi.org/10.1186/s12879-016-1762-1
DOI
|
8 |
Znaor L, Medic A, Binder S, Vucinovic A, Marin Lovric J, Puljak L. Pars plana vitrectomy versus scleral buckling for repairing simple rhegmatogenous retinal detachments. Cochrane Database Syst Rev 2019; 3: CD009562. https://doi.org/10.1002/14651858.CD009562.pub2
DOI
|
9 |
Lyall DAM, Hutchison BM, Gaskell A, Varikkara M. Intravitreal Ranibizumab in the treatment of choroidal neovascularisation secondary to ocular toxocariasis in a 13-year-old boy. Eye (Lond) 2010; 24: 1730-1731. https://doi.org/10.1038/eye.2010.131
DOI
|
10 |
Jee D, Kim KS, Lee WK, Kim W, Jeon S. Clinical features of ocular toxocariasis in adult Korean patients. Ocul Immunol Inflamm 2016; 24: 207-216. https://doi.org/10.3109/09273948.2014.994783
DOI
|
11 |
Ahn SJ, Woo SJ, Jin Y, Chang YS, Kim TW, Ahn J, Heo JW, Yu HG, Chung H, Park KH, Hong ST. Clinical features and course of ocular toxocariasis in adults. PLoS Negl Trop Dis 2014; 8: e2938. https://doi.org/10.1371/journal.pntd.0002938
DOI
|
12 |
Takakura A, Tessler HH, Goldstein DA, Guex-Crosier Y, Chan CC, Brown DM, Thorne JE, Wang R, Cunningham ET Jr. Viral retinitis following intraocular or periocular corticosteroid administration: a case series and comprehensive review of the literature. Ocul Immunol Inflamm 2014; 22: 175-182. https://doi.org/10.3109/09273948.2013.866256
DOI
|
13 |
Stewart JM, Cubillan LD, Cunningham ET, Jr. Prevalence, clinical features, and causes of vision loss among patients with ocular toxocariasis. Retina 2005; 25: 1005-1013. https://doi.org/10.1097/00006982-200512000-00009
DOI
|
14 |
Hostovsky A, Muni RH, Eng KT, Mulhall D, Leung C, Kertes PJ. Intraoperative dexamethasone intravitreal implant (Ozurdex) in vitrectomy surgery for epiretinal membrane. Curr Eye Res 2020; 45: 737-741. https://doi.org/10.1080/02713683.2019.1697454
DOI
|
15 |
Kong L, Peng HJ. Current epidemic situation of human toxocariasis in China. Adv Parasitol 2020; 109: 433-448. https://doi.org/10.1016/bs.apar.2020.01.016
DOI
|
16 |
Ahn SJ, Ryoo NK, Woo SJ. Ocular toxocariasis: clinical features, diagnosis, treatment, and prevention. Asia Pac Allergy 2014; 4: 134-141. https://doi.org/10.5415/apallergy.2014.4.3.134
DOI
|
17 |
Yoon DY, Woo SJ. Intravitreal administration of ranibizumab and bevacizumab for choroidal neovascularization secondary to ocular toxocariasis: a case report. Ocul Immunol Inflamm 2018; 26: 639-641. https://doi.org/10.1080/09273948.2016.1239744
DOI
|